Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481A |
| Therapy | Ibrutinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481A | chronic lymphocytic leukemia | predicted - resistant | Ibrutinib | Preclinical | Actionable | In a preclinical study, patients with BTK C481 were predicted to have resistance to Imbruvica (ibrutinib) since C481 is in the covalent binding site of the BTK inhibitor and C481A interferes with drug binding (PMID: 24869597). | 24869597 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (24869597) | Ibrutinib resistance in chronic lymphocytic leukemia. | Full reference... |